9-nitrocamptothecin. Antineoplastic antiviral DNA topoisomerase I inhibitor

Drugs of the Future

Volumn 24, Issue 12, 1999, Pages 1311-1323

  Pantazis, Panayotis ^a   Han, Zhiyong ^a   Chatterjee, Devasis ^a   Wyche, James H ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; RUBITECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CYSTITIS; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; NONHUMAN;

EID: 0033375796     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.12.560808     Document Type: Article

References (127)

1. Wani, M.C., Nicholas, A.W., Wall, M.E. Plant antitumor agents. 23. Synthesis and antileukemia activity of camptothecin analogs. J Med Chem 1986, 29: 2358-63.
2. Wall, M.E., Wani, M.C. Antineoplastic agents from plants. Annu Rev Pharmacol Toxicol 1977, 17: 117-32.
3. Jaxel, C., Kohn, K.W., Wani, M.C., Wall, M.E., Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989, 49: 1465-9.
4. Hsiang Y.-H., Liu, L.F., Wall, M.E., Wani, M.C., Kirshenbaum, S., Silber, R., Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 1989, 49: 4385-9.
5. Wall, M.E., Wani, M.C. Chemistry and antitumor activities of camptothecins. In: DNA Topoisomerases in Cancer, M. Potmesil and K.W. Kohn (Eds.), Oxford University Press, New York, 1991, 93-102.
6. Hinz, H.R., Harris, N.J., Natelson, E.A., Giovanella, B.C. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in human, dog and mouse. Cancer Res 1994, 54: 3096-100.
7. Pantazis. P., Harris, N., Mendoza, J., Giovanella, B. Conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human blood cells in vitro. Eur J Haematol 1994, 53: 246-8.
8. Pantazis, P., Harris, N., Mendoza, J., Giovanella, B. The role of pH and serum albumin in the metabolic conversion of 9-nitro-camptothecin to 9-aminocamptothecin by human hematopoietic and other cells. Eur J Haematol 1995, 55: 211-3.
9. Giovanella, B.C., Stehlin, J.S., Wall, M.E., Wani, M.C., Nicholas, A.W., Liu, L.F., Silber, R., Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246: 1046-8.
10. Pantazis, P., Hinz, H.R., Mendoza, J.T., Kozielski, A.J., Williams, L.J., Stehlin, J.S., Giovanella, B.C. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice by camptothecins. Cancer Res 1992, 52: 3980-7.
11. Pantazis, P., Early, J.A., Kozielski, A.J., Mendoza, J.T., Hinz, H.R., Giovanella, B.C. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: Differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 1993, 53: 1577-82.
12. Pantazis, P., Kozielski, A.J., Mendoza, J.T., Early, J.A., Hinz, H.R., Giovanella, B.C. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 1993, 53: 863-71.
13. Pantazis, P., Kozielski, A.J., Vardeman, D.M., Petry, E.R., Giovanella, B.C. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol Res 1993, 5: 273-81.
14. Pantazis, P., Kozielski, A., Rodriguez, R., Petry, E., Wall, E.M., Wani, M.C., Giovanella, B.C. Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts. Melanoma Res 1994, 4: 5-10.
15. Hsiang, Y.-H., Hertzberg, R., Hecht, S., Liu, L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260: 14873-8.
16. Caron, P., Wang, J.C. DNA topoisomerases as targets of therapeutics: A structural overview. In: Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy, T. Ando, H. Ikeda and M. Oguro (Eds.), CRC Press, Boca Raton, 1993, 1-18.
17. Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy, T. Ando, H. Ikeda and M. Oguro (Eds.), CRC Press, Boca Raton, 1993.
18. Topoisomerases: Biochemistry and Molecular Biology, L.F. Liu (Ed.), Advances in Pharmacology Vol. 29A, 1994.
19. Hsiang, Y.-H., Liu, L.F. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988, 48: 1722-6.
20. Hertzberg, R., Caranfa, M., Hecht, S. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 1989, 28: 4629-38.
21. Pommier, Y., Jaxel, C., Heise, C.R., Kerrigan, D., Kohn, K.W. Structure-activity relationship of topoisomerase I inhibition by camptothecin derivatives: Evidence for the existence of a ternary complex. In: DNA Topoisomerases in Cancer, M. Potmesil and K.W. Kohn (Eds.), Oxford University Press, New York, 1981, 121-32.
22. Jaxel, C., Capranico, G., Kerrigan, D., Kohn, K., Pommier, Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 1991, 226: 20418-23.
23. Porter, S.E., Champoux, J.J. The basis of camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res 1989, 17: 8521-32.
24. Champoux, J.J. DNA is linked to the rat liver nicking-closing enzyme by a phosphodiester bond to tyrosine. J Biol Chem 1981, 256: 4805-9.
25. Leteurtre, F., Fesen, M., Kohlhagen, G., Kohn, K.W., Pommier, Y. Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry 1994, 3: 8955-62.
26. Zhang, H., D'Arpa, P., Liu, L. A model for tumor killing by topoisomerase poisons. Cancer Cells 1990, 2: 23-7.
27. Hsiang, Y.-H., Lihou, M.G., Liu, L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989, 49: 5077-82.
28. Tsao, Y.-P., Russo, A., Nyamuswa, G., Silber, R., Liu, L.F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: Studies in a cell-free SV40 DNA replication system. Cancer Res 1993, 53: 5908-14.
29. Pantazis, P., Mendoza, J.T., Kozielski, A.J., Natelson, E.A., Giovanella, B.C. 9-Nitrocamptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro. Eur J Haematol. 1993, 50: 81-9.
30. Pantazis, P., Early, J.A., Mendoza, J.T., DeJesus, A.R., Giovanella, B.C. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res 1994, 54: 771-6.
31. Del Bino, G., Skierski, J.S., Darzynkiewicz, Z. Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG-1) leukemia cells. Cancer Res 1990, 50: 5746-50.
32. 2 arrest: Altered regulation of p34(cdc2)/cyclin B. Cancer Res 1992, 52: 1823-9.
33. Shimizu, T., O'Connor, P.M., Kohn, K.W., Pommier, Y. Unscheduled activation of cyclin B1/cdc2 kinase in human promyelocytic leukemia HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 1995, 55: 228-31.
34. Lanza, A., Tornaletti, S., Stefanini, M., Evans, H.H., Ricanati, M., Astaldi-Ricotti, J., Pedrini, A.M. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases. Carcinogenesis 1993, 14: 1759-63.
35. Gong, J., Ardelt, B., Traganos, F., Darzynkiewicz, Z. Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines. Cancer Res 1994, 54: 4285-8.
36. Houghton, J.A., Harwood, F.G., Houghton, P.J. Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. Cancer Res 1994, 54: 4967-73.
37. 2-phase of the cell cycle by 9-nitrocamptothecin. Lab Invest 1995, 73: 118-27.
38. Pandey, S., Wang, E. Cells en route to apoptosis are characterized by the upregulation of c-fos, c-myc, c-jun, cdc2 and RB phosphorylation, resembling events of early cell-cycle traverse. J Cell Biochem 1995, 58: 135-50.
39. Goldwasser, F., Bae, I., Valenti, M., Torres, K., Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995, 55: 2116-21.
40. Beidler, D.R., Chang, J.Y., Zhou, B.S., Cheng, Y.C. Camptothecin resistance involving steps subsequently to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res 1996, 56: 345-53.
41. Bertrand, R., O'Connor, P.M., Kerrigan, D., Pommier, Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 1992, 28A: 743-8.
42. Pantazis, P., Vardeman, D., Mendoza, J., Early, J., Kozielski, A., DeJesus, A.. Giovanella, B. Sensitivity of camptothecin-resistant human leukemia cells and tumors to anticancer drugs with diverse mechanisms of action. Leuk Res 1995, 19: 43-55.
43. Pantazis, P., Mendoza, J., DeJesus, A., Early, J., Shaw, M., Giovanella, B. Development of resistance to 9-nitrocamptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs. Anticancer Drugs 1994, 5: 473-9.
44. Pantazis, P., DeJesus, A., Early, J., Rodriguez, R., Chatterjee, D., Han, Z., Wyche, J., Giovanella, B. Development of human leukemia U-937 cell sublines resistant to doxorubicin: Induction of differentiation and altered sensitivities to topoisomerase-directed drugs. Anticancer Res 1995, 15: 1873-81.
45. Chaterjee, D., Wyche, J., Pantazis, P. Induction of apoptosis in malignant and camptothecin-resistant human cells. Ann NY Acad Sci 1996, 803: 143-56.
46. Beck, W.T. Unknotting the complexities of multidrug resistance: The involvement of DNA topoisomerases in drug action and resistance. J Natl Cancer Inst 1989, 81: 1683-5.
47. Tan, K.B., Mattern, M.R., Eng, W.-K., McCabe, F.L., Johnson, R.K. Nonreproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 1989, 81: 1732-5.
48. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L.F., Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 1990, 50: 7962-5.
49. Bartlett, N.L., Wasserman, T.H. Combined modality therapy. In: The Chemotherapy Source Book, M.C. Perry (Ed.), Williams & Wilkins, Baltimore, 1996, 109-26.
50. Musk, S.R.R., Steel, G.G. The inhibition of cellular recovery in human tumor cells by inhibitors of topoisomerase I. Br J Cancer 1990, 62: 364-7.
51. Boothman, D.A., Wang, M., Schea, R.A., Burrows, N.L., Strickfaden, S., Owens, J.K. Post-treatment exposure to camptothecin unbalanced the lethal effects of x-rays on radioresistant malignant melanoma cells. Int J Radiat Oncol Biol Phys 1992, 24: 939-48.
52. Boscia, R.E., Korbut, T., Holden, S.A., Ara, G., Teicher, B.A. Interaction of topoisomerase I inhibitors with radiation in cis-diaminedichloroplatinum(I)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int J Cancer 1993, 53: 118-23.
53. Falk, S.J., Smith, P.J. DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int J Radiat Biol 1992, 61: 749-57.
54. Del Bino, G., Bruno, S., Yi, P.N., Darzynkiewicz, Z. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prolif 1992, 25: 537-48.
55. Gorczyca, W., Gong, J., Ardelt, B., Traganos, F., Darzynkiewicz, Z. The cell cycle related differences in susceptibility of HL-60 cells. Cancer Res 1993, 53: 3186-92.
56. Hennequin, C., Giocanti, N., Balosso, J., Favaudon, Y. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res 1994, 54: 1720-8.
57. Kirichenko, A.V., Rich, T.A., Newman, R.A., Travis, E.L. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin. Cancer Res 1997, 57: 1929-33.
58. Boothman, D.A., Fukunaga, N., Wang, M. Down-regulation of topoisomerase I in mamalian cells following ionizing radiation. Cancer Res 1994, 54: 4618-26.
59. Lee, J.M., Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993, 90: 5742-6.
60. McIlwrath, A.J., Vasey, P.A., Ross, G.M., Brown, R. Cell cycle arrest and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res 1994, 54: 3718-22.
61. Sentman, C.L., Shutter, J.R., Hockenbery, D., Kanagawa, O., Korsmeyer, S.J. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991, 67: 879-88.
62. Strasser, A., Harris, A.W., Cory, S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 1991, 67: 889-99.
63. 2 checkpoint in p53-independent apoptosis induction by x-irradiation. Mol Cell Biol 1995, 15: 5849-57.
64. Hahn, G.M. Thermal enhancement of the actions of anticancer agents. In: Hyperthermia and Cancer, G.M., Hahn (Ed.), New York, Plenum Publishing Corp., 1992, 55-86.
65. Fisher, G.A., Hahn, G.M. Enhancement of cis-platinum(II)diaminedichloride cytotoxicity by hyperthermia. Natl Cancer Inst Monogr 1982, 61: 255-7.
66. Watanabe, N., Niitsu, Y., Umeno, H., Soneda, H., Yamauchi, N., Maeda, M., Urushizaki, I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 1988, 48: 650-3.
67. Niitsu, Y., Watanabe, N., Umeno, H., Sone, H., Neda, H., Yamauchi, N., Maeda, M., Urushizaki, I. Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis. Cancer Res 1988, 48: 654-7.
68. Tomasovic, S.P., Barta, M., Klostergaard, J. Neutral red uptake and clonogenic survival assays of the hyperthermia sensitization of tumor cells to tumor necrosis factor. Radiat Res 1989, 119: 325-37.
69. Fujimoto, S., Konno, O., Kobayashi, K., Kokubun, M., Shrestha, R.D., Kiuchi, S., Takahashi, M., Okui, K. Augmented antitumor effects of combined treatment with hyperthermia and tumor necrosis factor on human gastric cancer xenografted into nude mice. Int J Hyperthermia 1991, 7: 511-8.
70. Cohen, J.D., Robins, H.I., Schmitt, C.L. Tumoricidal interactions of hyperthermia with carboplatin, cisplatin and etoposide. Cancer Lett 1989, 44: 205-10.
71. Kampinga, H.H., Kruk, G.V.D., Konings, A.W.T. Reduced DNA break formation and cytotoxicity of the topoisomerase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide when combined with hyperthermia in human and rodent cell lines. Cancer Res 1989, 49: 1712-7.
72. Dynlacht, J.R., Wong, R.S.L., Albright, N., Dewey, W.C. Hyperthermia can reduce cytotoxicity from etoposide without a corresponding reduction in the number of topoisomerase II-DNA cleavable complexes. Cancer Res 1994, 54: 4129-37.
73. Valenzuela, M.H., Nuñez, M.I., Villalobos, M., Siles, E., McMillan, T.J., Pedraza, V., Ruiz de Almondovar, J.M. A comparison of p53 and p16 expression in human tumor cells treated with hyperthermia or ionizing radiation. Int J Cancer 1997, 72: 307-12.
74. Serrano, M., Hannon, G.J., Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366: 704-7.
75. Hinds, P.W., Dowdy, S.F., Eaton, E.N., Arnold, A., Weinberg, R.A. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994, 91: 709-13.
76. Teicher, B.A., Holden, S.A., Khandakar, V., Herman, T.S. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diaminedichloro-platinum(II)/heat/radiation] in a murine tumor. J Cancer Res Clin Oncol 1993, 119: 645-51.
77. Pantazis, P., Chatterjee, D., Han, Z., Wyche, J. Modulation of 9-nitrocamptothecin-induced apoptosis by hyperthermia in human leukemia HL-60 cells. Anticancer Drugs 1999, 10: 317-22.
78. Pantazis, P., Han, Z., Wyche, J. Schedule-dependent efficiency of thermochemotherapy in vitro with etoposide and heating at 43°C. Anticancer Res 1999, 19: 995-8.
79. Potential targets for new anticancer drugs. In: The Anticancer Drugs, W.B. Pratt, R.W. Ruddon, W.D. Ensminger, J. Maybaum (Eds.), Oxford University Press, New York, 1994, 306-36.
80. Warrell, R.P. Differentiation agents. In: The Chemotherapy Source Book, M.C. Perry (Ed.), Baltimore, Williams & Wilkins, 1996, 447-58.
81. Scott, R.E. Differentiation, differentiation/gene therapy and cancer. Pharmacol Ther 1997, 73: 51-65.
82. Nakaya, K., Chou, S., Kaneko, M., Nakamura, Y. Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells. Jpn J Cancer Res 1991, 82: 184-91.
83. Chou, S., Kaneko, M., Nakaya, K., Nakamura, Y. Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin. Biochem Biophys Res Commun 1990, 1656: 160-7.
84. McSheehy, P.M.J., Gervasoni, M., Lampasona, V., Erba, E., D'Incalci, M. Studies of the differentiation properties of camptothecin in the human leukaemic cells, K562. Eur J Cancer 1991, 27: 1406-11.
85. Aller, P., Rius, C., Mata, F., Zorilla, A., Cabañas, C., Bellon, T., Bernabeu, C. Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells. Cancer Res 1992, 52: 1245-51.
86. Singh, S., Razu, U., Mendoza, J., Pantazis, P., Aggarwal, B.B. Acquisition of cellular resistance to 9-nitrocamptothecin correlates with suppression of transcription factor NF-kappaB activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells. Anticancer Drugs 1998, 9: 703-14.
87. Kharbanda, S., Rubin, E., Gunji, H., Hinz, H., Giovanella, B., Pantazis, P., Kufe, D. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res 1991, 51: 6636-42.
88. Rubin, E., Pantazis, P., Bharti, T., Toppmeyer, D., Giovanella, B.C., Kufe, D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitrocamptothecin. J Biol Chem 1994, 269: 2433-9.
89. Pantazis, P., Mendoza, J.T., DeJesus, A., Rubin, E., Kufe, D., Giovanella, B. Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitrocamptothecin. Eur J Haematol 1994, 53: 135-44.
90. Mitchell, R.I., Tjian, R. Transcriptional regulation in mammalian cells by senescence-specific DNA binding proteins. Science 1989, 245: 371-8.
91. Zhang, H., Wang, J.C., Liu, L.F. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc Natl Acad Sci USA 1988, 85: 1060-4.
92. Merino, A., Madden, K.R., Lane, W.S., Champoux, J.J., Reinberg, D. DNA topoisomerase I is involved in both repression and activation of transcription. Nature 1993, 365: 227-32.
93. Schönfeld, S., Schulz, S., Nyce, J.W. Effects of inhibitors of topoisomerases I and II on DNA methylation and DNA synthesis in human colonic adenocarcinoma cells in vitro. Int J Oncol 1992, 1: 807-15.
94. Naveh-Many, T., Cedar, H. Active gene sequences are undermethylated. Proc Natl Acad Sci USA 1981, 78: 4246-50.
95. Riggs, A.D., Jones, P.A. 5-Methylcytocine, gene regulation, and cancer. Adv Cancer Res 1983, 40: 1-30.
96. Gieseler, F., Boege, F., Clark, M., Meyer, P. Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoietic cell differentiation. Toxicol Lett 1993, 67: 331-40.
97. Landau, M., Weizman, A., Zoref-Shani, E., Beery, E., Wasserman, L., Landau, O., Gavish, M., Brenner, S., Nordenberg, J. Antiproliferative and differentiating effects of benzodiazepine receptor ligands on B16 melanoma cells. Biochem Pharmacol 1998, 56: 1029-34.
98. Yang, Z-Y., Perkins, N.D., Ohno, T., Nabel, E.G., Nabel, G.J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med 1995, 1: 1052-6.
99. Pantazis, P., Chatterjee, D., Han, Z., Wyche, J. Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro. Neoplasia 1999, 1: 231-40.
100. Ligget, W.H., Sidransky, D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998, 16: 1197-206.
101. Castellano, M., Gabrielli, B.G., Hussussian, C.J., Dracopoli, N.C., Hayward, N.K. Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. J Invest Dermatol 1997, 109: 61-8.
102. Pantazis, P., Han, Z., Chatterjee, D., Wyche, J. Water-insoluble camptothecin analogs as potential antiviral drugs. J Biomed Sci 1999, 6: 1-7.
103. Pantazis, P. Camptothecin: A promising antiretroviral drug. J Biomed Sci 1996, 3: 14-9.
104. Moulton, S., Pantazis, P., Epstein, J.S., Sadaie, M.R. 9-Nitrocamptothecin inhibits in vitro induction of activation of the human immunodeficiency virus type 1 (HIV-1) in latently infected human T lymphocytes. AIDS Res Hum Retroviruses 1998, 14: 39-49.
105. Sadaie, M.R., Doniger, J., Hung, C-L., Pantazis, P. 9-Nitrocamptothecin (9-NC) selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9-NC-resistant U937 monocytoid cells. AIDS Res Hum Retroviruses 1999, 14: 239-45.
106. Burke, T.G., Mi, Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Analyt Biochem 1993, 212: 285-7.
107. Mi, Z., Burke, T.G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 1994, 33: 10325-36.
108. Mi, Z., Burke, T.G. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: A frequency-domain fluorescence spectroscopic study. Biochemistry 1994, 33: 12540-5.
109. Wani, M.C., Ronman, P.E., Lindley, L.T., Wall, M.E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 1980, 23: 554-60.
110. Giovanella, B.C., Hinz, H.R., Kozielski, A.J., Stehlin, J.S., Silber, R., Potmesil, M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S) camptothecin. Cancer Res 1991, 51: 3052-5.
111. Cao, Z., Harris, N., Kozielski, A., Vardeman, D., Stehlin, J.S., Giovanella, B.C. Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J Med Chem 1998, 41: 31-7.
112. Han, Z., Cao, Z., Chatterjee, D., Wyche, J., Pantazis, P. Propionate and butyrate esters of camptothecin and 9-nitro-camptothecin as antileukemia prodrugs in vitro. Eur J Haematol 1999, 62: 246-55.
113. Verschraegen, C.F., Natelson, E.A., Giovanella, B.C., Kavanagh, J.J., Kudelka, A.P., Freedeman, R.S., Edwards, C.L., Ende, K., Stehlin, J.S. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 1998, 9: 36-44.
114. Verschraegen, C.F., Gupta, E., Loyer, E., Kavanagh, J.J., Kudelka, A.P., Freedman, R.S., Edwards, C.L., Harris, N., Steger, M., Steltz, V., Giovanella, B.C., Stehlin, J.S. A phase II and pharmacologic study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs 1999, 10: 375-83.
115. Stehlin, J.S., Giovanella, B.C., Natelson, E.A., De Ipolyi, P.D., Coil, D., Davis, B., Wolk, D., Wallace, P., Trojacek, A. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999, 14: 821-31.
116. Javaherian, L., Liu, L.F. Association of eukaryotic DNA topoisomerase I with nucleosomes and chromosomal proteins. Nucleic Acids Res 1983, 11: 461-72.
117. Rose, K.M., Szopa, J., Han, F.S., Cheng, Y.C., Richter, A., Scheer, U. Association of DNA topoisomerase I and RNA polymerase I: A possible role for topoisomerase I in ribosomal gene transcription. Chromosoma 1998, 96: 411-6.
118. Bharti, A.K., Olson, M.O.J., Kufe, D.W., Rubin, E. Identification of a nucleolin binding site in human topoisomerase I. J Biol Chem 1996, 271: 1993-7.
119. Simmons, D.T., Melendy, T., Usher, D., Stillman, B. Simian virus 40 large antigen binds to topoisomerase I. Virology 1996, 222: 365-74.
120. Haluska, P., Saleem, A., Edwards, T.K., Rubin, E.H. Interaction between the N-terminus of human topoisomerase I and SV40 large T antigen. Nucleic Acids Res 1998, 26: 1841-7.
121. Gobert, C., Bracco, L., Rossi, F., Olivier, M., Tazi, J., Lavelle, F., Larsen, A.K., Riou, J.F. Modulation of DNA topoisomerase I activity by p53. Biochemistry 1996, 35: 5778-86.
122. Arbor, A., Kaku, S., Kulesz-Martin, M. Wild-type and mutant forms of p53 activate human topoisomerase I: A possible mechanism for gain of function in mutants. Cancer Res 1998, 58: 2091-4.
123. Pommier, Y., Kolhagen, G., Wu, C., Simmons, D.T. Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by simian virus 40 large T antigen. Biochemistry 1998, 37: 3818-23.
124. Herben, V.M., Ten-Bokkel Huinink, W.W., Schellens, J.H., Beijnen, J.H. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors. Pharm World Sci 1998, 20: 161-72.
125. Natelson, E.A., Giovanella, B.C., Verschraegen, C.F., Fehir, K.M., Delpolyi, P.D., Harris, N., Stehlin, J.S. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 1996, 803: 224-30.
126. Lamond, J.P., Wang, M., Kinsella, T.J., Boothman, D.A. Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors. Int J Radiat Oncol Biol Phys 1996, 36: 369-76.
127. Kirichenko, A.V., Rich, T.A. Radiation enhancement by 9-aminocamptothecin: The effect of fractionation and timing of administration. Int J Radiat Oncol Biol Phys 1999, 44: 659-64.